PRIMARY BILIARY CHOLANGITIS: DIAGNOSIS AND MANAGEMENT Project ID:
|
|
- Clarence Webb
- 5 years ago
- Views:
Transcription
1 ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Purdue University College of Pharmacy and the Chronic Liver Disease Foundation (CLDF). Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians. Purdue University College of Pharmacy designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity. NURSING STATEMENT Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center s Commission on Accreditation. Release: January 19, 2018 Expiration: January 19, 2019 DISCLOSURE OF CONFLICTS OF INTEREST All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff, and reviewers of the Chronic Liver Disease Foundation and Purdue University College of Pharmacy have no relationships to disclose. The opinions expressed in this enduring material are those of the faculty and do not necessarily represent the views of the Purdue University College of Pharmacy. The information is presented for the purpose of advancing the attendees professional development. LEARNER ASSURANCE STATEMENT The Purdue University College of Pharmacy is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members significant relationships with drug or device manufacturer(s). OBJECTIVES After reading and studying this newsletter, the participant should be able to: Describe evolving patient management strategies for primary biliary cholangitis (PBC) Discuss the latest treatment algorithms for PBC and apply them to clinical practice AUTHORS Ira M. Jacobson, MD Professor of Medicine Director of Hepatology NYU School of Medicine New York, New York Andres F. Carrion, MD Director of Hepatology Assistant Professor of Medicine Division of Gastroenterology and Hepatology Texas Tech University Health Sciences Center El Paso El Paso, Texas Cynthia Levy, MD Associate Professor of Medicine Division of Hepatology University of Miami Miller School of Medicine Miami, Florida REVIEWED BY Zobair M. Younossi, MD, MPH, FACG Member, Board of Trustee of Chronic Liver Disease Foundation (CLDF) Co-chair of International Coalition of Hepatology Educators (IC-HEP) Board Member, ACG Institute AUTHOR DISCLOSURES Ira Jacobson, MD Research Support: Genfit, Gilead, Merck Consultant: AbbVie, Bristol-Myers Squibb, Gilead, Intercept, Merck, Trek Speakers Bureau: Gilead, Intercept, Merck Andres Carrion, MD Consultant/Speakers Bureau: Alexion, Bristol-Myers Squibb, Intercept, Merck Advisory Board Membership: Gilead, Intercept Cynthia Levy, MD Grants/Research Support: CymaBay, Gilead, GlaxoSmithKline, Intercept, Novartis, NGM, Shionogi, Shire, Tobira Consultant: Intercept Advisory Board Membership: Intercept, Novartis Honorarium Recipient: UpToDate royalties Editorial Board Involvement: Liver Transplantation 1
2 Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is the most common chronic cholestatic liver disease in adults in the United States. The disease disproportionately affects middle-aged women (9:1 female-to-male ratio). In September 2015, a multi-societal position paper established the change in the disease s nomenclature while maintaining the commonly used acronym PBC. 1 Without pharmacological treatment, progressive fibrosis characterizes the natural history of PBC. Characterized by progressive immune-mediated inflammatory destruction of septal and interlobular bile ductules, the fundamental pathophysiological mechanism for PBC is likely related to a complex interaction between unidentified environmental triggers and genetic susceptiblility. Molecular mimicry, loss of tolerance, and dysregulated immune attacks directed against the E2 subunit of pyruvate dehydrogenase complex (PDC-E2) appear to be the cornerstone of PBC pathogenesis. 2 The result, at least microscopically, reflects the new terminology and can be identified by nonsuppurative cholangitis manifesting biochemically as cholestasis. Without pharmacological treatment, progressive fibrosis characterizes the natural history of PBC. Clinical features are nonspecific and include fatigue, pruritus, right upper quadrant abdominal pain, dyslipidemia, bone mineral density loss, xanthelasmas and, rarely, xanthomas. PBC diagnosis may be established by two of the following three criteria in the absence of a cholestatic drug reaction or biliary obstruction: a) biochemical evidence of cholestasis (otherwise unexplained elevation of serum alkaline phosphatase); b) presence of autoantibodies, typically anti-mitochondrial antibodies (AMA); and, c) histological findings of non-suppurative destructive cholangitis. 3 Characteristic histological features, previously thought to be necessary for establishing a PBC diagnosis, are not mandatory if the other two diagnostic criteria are satisfied. Furthermore, the pathognomonic florid duct lesion is only present in a minority of PBC patients, particularly during early stages. 4 Even when seen, this lesion, characterized by intraepithelial lymphocyte infiltration with visible bile duct injury, may be present in only one portal tract out of whatever number was obtained in the biopsy specimen. Among many hepatologists, the trend has been to rely upon noninvasive assessment of fibrosis, especially when the diagnosis of PBC can be established the first two criteria outlined above. Vibration-controlled transient elastography (Fibroscan ) has been shown to be reliable and may have particular utility for monitoring fibrosis progression. 5 Vibration-controlled transient elastography (Fibroscan ) has been shown to be reliable and may have particular utility for monitoring fibrosis progression. 5 It is important to recognize that AMA, the hallmark autoantibody of PBC, may not be detectable in approximately 5 to 10% of patients with the disease (the so-called AMA-negative PBC), in which histology is mandatory to establish the diagnosis. Most patients with AMA-negative PBC have antinuclear antibodies (ANA). Among these, two subtypes of ANA, nuclear pore membrane protein gp210, and nuclear body protein sp100, are relatively insensitive but highly specific (>95%) markers of PBC (PLOS One article below), and may help corroborate the diagnosis. 6 Ursodeoxycholic acid (UDCA), the first pharmacological agent licensed for PBC treatment, has proven to alter the natural history of the disease significantly when administered orally at a 2
3 dose of mg/kg/day. Important outcomes associated with UDCA therapy in PBC include reduced fibrosis progression, diminished need for liver transplantation (LT), and improved LT-free survival. Nevertheless, up to 40% of PBC patients who are treated with UDCA for at least a year have an inadequate biochemical response and experience lesser benefits on long-term outcomes. 7 Response to pharmacologic therapy is assessed predominantly by reductions in serum alkaline phosphatase and bilirubin levels, two biochemical markers that accurately predict long-term outcomes in PBC. 8 Incomplete responders are at higher risk for progression towards biliary cirrhosis and end-stage liver disease and are more likely to develop hepatocellular carcinoma compared to those who respond to UDCA. 9 Other recommendations in the management of patients with PBC are listed in Table 2. The PBC GLOBE score (available at is a newly validated non-invasive assessment tool that uses readily available and objective variables (age, bilirubin, albumin, alkaline phosphatase, and platelet count) for accurately identifying patients at risk for clinically important outcomes, such as the need for LT and mortality within the next three, five, and 10 years. 10 An online calculator can be used to derive this score rapidly in any patient for whom recent laboratory parameters are available. It may be particularly useful as an aid to monitoring the course of a patient s response to UDCA treatment and thereby assess the need for additional therapies. Obeticholic acid (OCA) was licensed on May 27, 2016 by the Food and Drug Administration. OCA is currently indicated for treating PBC, in combination with UDCA, in adults with an inadequate biochemical response to UDCA for at least 12 months, or as monotherapy in adults who cannot tolerate UDCA. OCA is a selective farnesoid X receptor (FXR) agonist derived from the naturally occurring chenodeoxycholic acid, an endogenous FXR ligand. FXR is a member of the nuclear bile acid receptor superfamily expressed in high levels in hepatocytes and enterocytes in the terminal ileum and its activation results in suppression of cholesterol 7 alpha-hydroxylase (CYP7A1) and transcription of fibroblast growth factor (FGF) 19. CYP7A1 is the rate-limiting enzyme in bile acid synthesis from cholesterol. Accordingly, FXR activation markedly reduces the bile acid pool. Similarly, increased levels of FGF19 inhibit de novo synthesis of bile acids; nevertheless, this hormone also regulates several metabolic pathways, including insulin sensitivity and lipid metabolism. Furthermore, in animal models, FXR activation has proven to result in fibrosis regression. 11 The recommended OCA dosing is summarized in Table 1. Table 2. General recommendations for management of patients with PBC. 3 Complication Pruritus Fatigue Dyslipidemia Sicca syndrome Osteopenia / osteoporosis Gastroesophageal varices Recommendation First line: bile acid sequestrants (i.e., cholestyramine or cholestipol) Second line: rifampicin, naltrexone, sertraline Evaluate for potential causes including comorbidities, medications, depression, itching. May use modafinil (off label) Statins if needed, based on individual risk factors for cardiovascular disease First line: artificial tears/ artificial saliva Second line: pilocarpine or cevimeline for dry eyes/ mouth, cyclosporine ophthalmic for dry eyes Baseline and regular screening every 2 3 years with bone mineral density scan Calcium 1500 mg/day and vitamin D 1000 IU/ day supplementation for peri- and post-menopausal women Bisphosphonates for patients with osteoporosis Initiate screening with upper endoscopy once cirrhosis is diagnosed or Mayo risk score >4.1 or platelets <140,000 In the randomized, placebo-controlled POISE trial, the primary composite end point was an alkaline phosphatase level of less than 1.67 times the upper limit of the normal range (the inclusion criteria included alkaline phosphatase above this level), with a reduction of at least 15% from baseline, and a total bilirubin level at or below the upper limit of the normal range at 12 months. In the trial OCA, Hepatocellular carcinoma Screening with liver ultrasonography every 6 12 months for individuals with cirrhosis or Mayo risk score >4.1. Males and UDCAnonresponders appear to be at increased risk. 3
4 administered with UDCA or as monotherapy for 12 months, resulted in attainment of the primary endpoint in 47% of individuals treated with 10 mg/day, 46% of those started at 5 mg/day with uptitration to 10 mg, and 10% of those that received the placebo. 12 The findings of this trial, which compared two different dosing strategies for OCA, led to the approval of a starting dose of 5 mg/ day with upward titration to 10 mg/day after at least 3 months as needed to improve upon the biochemical response, provided the drug is being tolerated well. Table 1. Recommended doses for UDCA and OCA for treating PBC. No cirrhosis and compensated cirrhosis Decompensated cirrhosis UDCA mg/kg/day mg/kg/day The main side effect of OCA is pruritus, which occurred in 56% of patients who started on 5 mg/ day in the POISE trial, 68% in patients who received an initial dose of 10 mg/day, and 38% in placebo recipients. Discontinuation rates due to pruritus occurred in 10% of the 10 mg group, 1% of the 5 mg group, and 0% of the placebo recipients. Importantly, the package insert for OCA stipulates a dose reduction to 5 mg once weekly in patients with moderate to severe hepatic dysfunction, as OCA is predominantly excreted by the liver (87%). A recent safety report to providers described 19 patients OCA 5 mg/day, titrate up to 10 mg/day after three months if tolerated 5 mg/week, titrate up to 5 mg twice weekly after three months and subsequently to 10 mg twice weekly if tolerated with fatal outcomes, and an additional 11 cases of serious liver injury, associated with OCA therapy. Where details were available, a large number of these cases (including most of the fatalities) were associated with daily instead of the required weekly dosing in PBC patients with moderate to severe hepatic dysfunction at baseline. 13 Although a causal relationship between mortality and OCA has not yet been established and is under evaluation, this development underscores the need for providers to be familiar with the guidelines for dosing outlined in the product s package insert. Several other drugs are currently under evaluation for treating patients with PBC and inadequate response to UDCA. Fenofibrate, a PPAR-alpha agonist, and bezafibrate, an agonist of all three major PPAR receptors (alpha, delta and gamma), have been shown to have beneficial biochemical effects 14,15. A recent clinical trial of bezafibrate given for 24 months demonstrated normalization of alkaline phosphatase in 67% and normal levels of all biochemical parameters (bilirubin, ALT, AST, alkaline phosophatase, albumin and prothrombin time) in 30%. 15 Another recent agent, seladelpar (MBX-8025), a PPAR-delta agonist, effected substantial reductions or even normalization of alkaline phosphatase in a phase 2 trial, but were associated with grade 3 transaminase elevations at doses of mg/day. 16 At reduced doses of 5-10 mg given for 12 weeks, reductions in alkaline phosphatase were 39-45% without grade 2 or 3 transaminase elevations and phase 3 studies are planned. 17 At the present time, however, only OCA remains approved for patients with an inadequate response to ursodeoxycholic acid. PBC is the sixth leading indication for LT in the United States; pharmacological therapy has resulted in a steady decline in the number of individuals requiring LT since UDCA approval. 18 Outcomes following LT for PBC are excellent and have been considered the benchmark for patient and allograft survival to which other indications for LT are compared. Although recurrence post-lt is relatively common, it has no significant impact on survival. Recent data from a retrospective study suggest that preventive administration of UDCA may markedly diminish recurrence of PBC 10 years post- LT. 19 These data need to be corroborated by prospective studies and there are currently no data on the role of OCA and prevention of recurrent PBC post-lt. In Summary: PBC is a heterogeneous disease and not all patients respond to firstline therapy with UDCA. Secondline therapy with OCA is available for nonresponders and for those who are intolerant to UDCA. Care for PBC patients must be individualized based on staging and appropriate risk stratification. 4
5 REFERENCES 1. Meglasson MD, Smith KM, Nelson D, Erecinska M. alpha-glycerophosphate shuttle in a clonal beta-cell line. The American Journal of Physiology 1989;256:E Shigematsu H, Shimoda S, Nakamura M, et al. Fine specificity of T cells reactive to human PDC-E peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. Hepatology 2000;32: Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009;50: Kaplan MM, Gershwin ME. Primary biliary cirrhosis. The New England Journal of Medicine 2005;353: Poupon R. Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis. Dig Dis 2015;33(suppl 2): Zhao FR, Hu Q, Chen WX. Meta-analysis Assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. Shi-Ling Hu. PLOS One 2014;9: Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48: Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147: e5; quiz e Kuiper EM, Hansen BE, Adang RP, et al. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. European Journal of Gastroenterology & Hepatology 2010;22: Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015;149: e Fausther M, Dranoff JA. New insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout mice. Journal of Hepatology 2011;55: Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. The New England Journal of Medicine 2016;375: Cheung AC, Lapointe-Shaw L, Kowgier M, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther Jan;43(2): Corpechot C, Chazouilleres O, Rousseau A et al. A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso). J. Hepatology 2017;66:S Jones D, Boudes PF, Swain MG et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-ofconcept study. Lancet Gastro and Hepatol 2017;2, No 10: Hirschfield G., Bowlus C., Harrison S. et al. Treatment Efficacy and Safety of Low Dose Seladelpar a Selective PPAR-δ Agonist, in Patients with Primary Biliary Cholangitis: 12-week Interim Analysis of an International, Randomized, Dose Ranging, Phase 2 Study. Annual Meeting of the American Association for the Study of Liver Diseases, Washington D.C. October 21, 2017, abstract LB Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2007;5: Bosch A, Dumortier J, Maucort-Boulch D, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. Journal of Hepatology 2015;63: If you wish to receive acknowledgement of participation for this activity, please complete the posttest, evaluation form, and request for credit by clicking the link below ACCREDITATION 5
Diagnosis and Management of PBC
Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in
More informationNew insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine
New insights in pathogenesis and therapy of primary biliary cholangitis Keith D. Lindor Dean Professor of Medicine OUTLINE PBC Epidemiology Diagnosis Treatment Incidence of PBC and PSC Trends Boonstra
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationShifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity
Overview Shifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity In this video series, Kris Kowdley, MD, and Seth Sclair, MD, share insight into changes in the management of patients with primary
More informationObeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope Background: April 21, 2016 Primary biliary cholangitis
More informationProgram Disclosure. This activity is supported by an educational grant from Intercept Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership
More informationPrimary biliary cholangitis
A guide to Primary biliary cholangitis Miss Jennifer Hayden, Autoimmune Liver Disease Clinical Nurse Specialist Professor Gideon M Hirschfield, Professor and Consultant Transplant Hepatologist Centre for
More informationRisk stratification in PBC
Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis What is primary biliary cholangitis? Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease. When a person has PBC, the immune
More informationPBC treatment: the present and future. Maggie Bassendine Professor of Hepatology
PBC treatment: the present and future Maggie Bassendine Professor of Hepatology Primary biliary cirrhosis 20-25yrs OLT/ Death Symptoms: Fatigue, itching, jaundice Autoimmune disease: Focal small bile duct
More informationOverview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN
Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal
More informationOCALIVA (obeticholic acid) oral tablet
OCALIVA (obeticholic acid) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationKa-Shing Cheung, MBBS, MPH 1, Wai-Kay Seto, MD 1,2, James Fung, MD 1,2, Ching-Lung Lai, MD 1,2 and Man-Fung Yuen, MD, PhD 1,2
Citation: (2017) 8, e100; doi:10.1038/ctg.2017.23 Official journal of the American College of Gastroenterology www.nature.com/ctg Prognostic Factors for Transplant-Free Survival and Validation of Prognostic
More informationCurrent Concepts in the Management and Treatment of PBC & PSC
Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationSubject: Obeticholic Acid (Ocaliva ) Tablet
09-J2000-65 Original Effective Date: 09/15/16 Reviewed: 07/11/18 Revised: 08/15/18 Subject: Obeticholic Acid (Ocaliva ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationMorning Report Presentation. Sarah Hughes, MD January 11, 2005
Morning Report Presentation Sarah Hughes, MD January 11, 2005 Primary Biliary Cirrhosis! PBC is a chronic, progressive, cholestatic liver disease of unknown cause that usually affects middle-aged women
More informationEfficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study
Efficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study Bowlus CL, Neff G, Aspinall R, Galambos M, Goel A, Hirschfield G, Kremer AE, Mayo MJ, Swain
More informationPrimary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS
Primary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS Nikolaos T. Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD Associate Professor and Chief, Division of Gastroenterology and Hepatology
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationIn primary biliary cholangitis (PBC), progression
HEPATOLOGY COMMUNICATIONS, VOL. 2, NO. 6, 2018 Clinical Application of the GLOBE and United Kingdom-Primary Biliary Cholangitis Risk Scores in a Trial Cohort of Patients With Primary Biliary Cholangitis
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationSingle Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785
Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment
More informationTREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited
More informationPrimary Biliary Cirrhosis
Primary Biliary Cirrhosis What is Primary Biliary Cirrhosis? Primary biliary cirrhosis (PBC) is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver called the
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationHépatopathies auto-immunes
16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationAutoimmune and cholestatic liver diseases
Autoimmune and cholestatic liver diseases Prof. Tom Hemming Karlsen Research Institute of Internal Medicine & Department of Transplantation Medicine University of Oslo & Oslo University Hospital, Norway
More informationManagement of cholestatic diseases Today and tomorrow
12th Paris Hepatology Conference Management of cholestatic diseases Today and tomorrow Paris 15 January 2019 U. Beuers Department of Gastroenterology & Hepatology Tytgat Institute for Liver and Intestinal
More informationEASL International Liver Congress Paris, France 14 April 2018
NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients With Biopsy-Confirmed NASH, Which is Preceded By Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationPrimary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study
LINDOR ET AL. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases Keith D. Lindor 1, Christopher L. Bowlus 2, James Boyer 3, Cynthia Levy 4,
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationNoncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
More informationTitle: stratification and treatment of primary biliary cholangitis. Authors: Javier Martínez, Lara Aguilera, Agustín Albillos
Title: Risk stratification and treatment of primary biliary cholangitis Authors: Javier Martínez, Lara Aguilera, Agustín Albillos DOI: 10.17235/reed.2018.5662/2018 Link: PubMed (Epub ahead of print) Please
More informationTABLE OF CONTENTS SYMPOSIUM AGENDA. Diagnosis, Stratification of Risk, and Initial Treatment in PBC
PBC Novel Pathways for Treatment of Cholestatic Liver Disease TABLE OF CONTENTS Faculty Biographies SYMPOSIUM AGENDA Introduction Kris V. Kowdley, MD Diagnosis, Stratification of Risk, and Initial Treatment
More informationHepatic Transporter Proteins involved in Bile Formation
Bile salt synthesis Hepatic Transporter Proteins involved in Bile Formation Basolateral membrane transporter proteins fx: NTCP uptake of bile salts OATP bulky organic anions Canalicular membrane transporter
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationPrimary biliary cirrhosis (PBC) is an autoimmune
Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study Li-Na Zhang, 1,2 * Tian-Yan Shi, 1,2 * Xu-Hua Shi, 1,2 Li Wang,
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationI have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES
LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationTitle: Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA
Title: Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA Authors: Weijia Duan, Xiaojuan Ou, Xiaoming Wang, Yu Wang, Xinyan
More informationAn Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications
REVIEW An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications Naim Alkhouri, M.D.,*, and Andrea Scott, B.S.* Nonalcoholic fatty liver disease (NAFLD)
More informationPrimary biliary cholangitis (PBC), previously known as primary
Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis Runalia Bahar, MD, Kimberly A. Wong, MD, Chung H. Liu, and Christopher L. Bowlus, MD Dr Bahar is a hospitalist
More informationLiver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management. Emma Pham, PA-C
Liver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management Emma Pham, PA-C Case: JL (jaundiced lady) A 72 year old woman presents to her primary care provider
More informationObeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks Evidence Report July 26, 2016 Institute for Clinical and Economic
More informationTowards Precision Medicine in Primary Biliary Cholangitis
Riunione Monotematica A.I.S.F. 2016 THE FUTURE OF LIVER DISEASES: Beyond HCV is there a role for the hepatologist? 14 th October 2016 Towards Precision Medicine in Primary Biliary Cholangitis Marco Carbone,
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationPrimary Biliary Cholangitis in Motion Meeting
Primary Biliary Cholangitis in Motion Meeting The PBC in Motion meeting took place on 10 th March 2018 in Heathrow, UK Chair People: Dave Jones, 1 Luigi Muratori 2 Speakers: Achim Kautz, 3 Gideon Hirschfield,
More informationENDOCRINOLOGY FOR PRIMARY CARE
ENDOCRINOLOGY FOR PRIMARY CARE Las Vegas, Nevada The Cosmopolitan February 27 March 1, 2015 Participating Faculty Gregory A. Brent, MD Professor, Departments of Medicine and Physiology David Geffen School
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationEpidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015
Citation: (2017) 8, e116; doi:10.1038/ctg.2017.43 Official journal of the American College of Gastroenterology www.nature.com/ctg Epidemiology and Natural History of Primary Biliary Cholangitis in the
More informationCLINICAL ENDOCRINOLOGY FOR PRIMARY CARE
CLINICAL ENDOCRINOLOGY FOR PRIMARY CARE Walt Disney World Resort, Florida Disney s Grand Floridian Resort & Spa November 14 16, 2014 Participating Faculty Veronica Piziak, MD, PhD Professor of Medicine
More informationAESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD
747-207 AESOP Overview and Inclusion/ Criteria Richard Pencek, PhD Sr Director, Clinical Research, Intercept Pharmaceuticals, Inc. 2 PSC Forum 2 AESOP: A Phase 2 Randomized, Placebo-Controlled Trial, Dose-Finding
More informationHow the concept of biochemical response influenced the management of primary biliary cholangitis over time
ORIGINAL ARTICLE How the concept of biochemical response influenced the management of primary biliary cholangitis over time W.J. Lammers 1 *, M. Leeman 1, C.I.J. Ponsioen 2, K. Boonstra 2, K.J. van Erpecum
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationFatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
More informationProlonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis
American Journal of Gastroenterology ISSN 0002-9270 C 2004 by Am. Coll. of Gastroenterology doi: 10.1111/j1572-0241.2004.04047.x Published by Blackwell Publishing Prolonged Follow-Up of Patients in the
More informationEASL GUIDELINES PBC CLINIC PBC CLINIC EASL GUIDELINES. Hepatologist and PBC specialist Professor David Jones of Newcastle University agrees:
EASL Clinical Practice Guidelines: The Diagnosis and management of patients with Primary Biliary Cholangitis In lay terms: what does it mean for the patient? The new EASL (European Association for Study
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationA Review of Liver Function Tests. James Gray Gastroenterology Vancouver
A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationColangitis Esclerosante Primaria: Manejo Clínico y Endoscópico
Colangitis Esclerosante Primaria: Manejo Clínico y Endoscópico Andrés Cárdenas, MD, MMSc, PhD, AGAF, FAASLD GI / Liver Unit, Hospital Clinic Institut de Malalties Digestives i Metaboliques Associate Professor
More informationWELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here.
WELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here. Photograph of an actual patient What is OCALIVA? OCALIVA is a prescription medicine used to
More informationPrimary Sclerosing Cholangitis Medical Management
Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive
More informationTreatment of Chronic Cholestasis: What We Know and What We Will Know?
REVIEW Treatment of Chronic Cholestasis: What We Know and What We Will Know? James L. Boyer HISTORICAL PERSPECTIVES For many years, the treatment of cholestatic liver disease was limited to surgical relief
More informationIdiopathic adulthood ductopenia manifesting as jaundice in a young male
Idiopathic adulthood ductopenia manifesting as jaundice in a young male Deepak Jain*,1, H. K. Aggarwal 1, Avinash Rao 1, Shaveta Dahiya 1, Promil Jain 2 1 Department of Medicine, Pt. B.D. Sharma University
More informationTHBA Platform - Bile acid imbalance
- Bile acid imbalance Bile acids play an important role in maintaining human health by means of signaling molecules in the regulation of bile formation, liver function and metabolism. The detergent effect
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationStudy Design to Validate Biomarkers of Therapeutic Response in Pre-cirrhotic NASH
Study Design to Validate Biomarkers of Therapeutic Response in Pre-cirrhotic NASH Brent A. Neuschwander-Tetri, MD, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology and Hepatology
More informationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Original Article A -Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis F. Nevens, P. Andreone, G. Mazzella, S.I. Strasser, C. Bowlus, P. Invernizzi, J.P.H. Drenth, P.J. Pockros, J. Regula,
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationSarah Landes October 23, 2014
Sarah Landes October 23, 2014 A T-cell mediated inflammatory destruction of intralobular bile ducts progressively leading to cholestasis and cirrhosis 9:1 F to M ratio Mostly diagnosed between 30-60 years
More informationHOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO
HOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO The identification of abnormal liver enzymes usually indicates liver damage but rarely
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationExtrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock.
Extrahepatic Biliary Obstruction Stones Tumors Ductal Diseases: Ductal Diseases: Primary Biliary Primary Biliary Cirrhosis Cirrhosis Sclerosing Cholangitis Sclerosing Cholangitis Acute Injury: Viral Hepatitis
More informationInterpreting Liver Function Tests
PSH Clinical Guidelines Statement 2017 Interpreting Liver Function Tests Dr. Asad A Chaudhry Consultant Hepatologist, Chaudhry Hospital, Gujranwala, Pakistan. Liver function tests (LFTs) generally refer
More informationMR Elastography of Liver
MR Elastography of Liver Sudhakar K. Venkatesh, MD, FRCR Professor of Radiology Mayo Clinic College of Medicine Consultant, Abdominal Division Radiology, Mayo Clinic Rochester, MN, USA 19 th May 2018 2018
More informationdoi: /s
doi: 10.1007/s10620-013-2734-6 Harada - 1 - Clinicopathological significance of serum fractalkine in primary biliary cirrhosis Kenichi Harada 1), Yuko Kakuda 1), Minoru Nakamura 2), Shinji Shimoda 3),
More informationPutting NICE guidance into practice. Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443)
Putting NICE guidance into practice Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443) Published: April 2017 Summary Obeticholic acid is recommended as an option
More informationCholestatic Liver Diseases: Update on Diagnosis and Management. Cholestatic Liver Diseases: Location of Injury Determines Phenotype
Cholestatic Liver Diseases: Update on Diagnosis and Management R. Todd Stravitz, M.D. Hume-Lee Transplant Center Section of Hepatology Virginia Commonwealth University Cholestatic Liver Diseases: Location
More informationHHS Public Access Author manuscript Hepatology. Author manuscript; available in PMC 2017 March 01.
Febuxostat-Induced Acute Liver Injury Matt Bohm, DO, Raj Vuppalanchi, MD, Naga Chalasani, MD, and Drug Induced Liver Injury Network (DILIN) Department of Medicine, Indiana University School of Medicine,
More informationPrimary biliary cholangitis (PBC)
The PBC Network Primary biliary cholangitis (PBC) Living with your diagnosis Officially endorsed and reviewed by About this guide The European Association for the Study of the Liver (EASL) is a major European
More informationBiomarkers of PSC. Steve Helmke, Ph.D.
Biomarkers of PSC Steve Helmke, Ph.D. steve.helmke@ucdenver.edu Biomarkers of PSC Currently Used in Clinical Practice Biomarkers Used in Prognostic Models of PSC Wiesner et al, 1989 Age Bilirubin Biopsy
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationTreatment of chronic hepatitis delta Case report
Treatment of chronic hepatitis delta Case report George Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National and Kapodistrian University of Athens, Director of Academic Department
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationACCME/Disclosures. PBC and PSC Revisited 4/6/2016. Primary Biliary Cirrhosis Cholangitis (PBC)
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Original Article A -Controlled Trial of in Primary Biliary Cholangitis C. Corpechot, O. Chazouillères, A. Rousseau, A. Le Gruyer, F. Habersetzer, P. Mathurin, O. Goria, P. Potier, A. Minello, C. Silvain,
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More information